Eli Lilly Reports Strong Q2, Boosts FY2024 Outlook

Key Highlights:

WEB Revenue increase of 36% driven by Mounjaro Zepbound and Verzenio

Net profit surged 68%

Raised full-year revenue guidance by $2 billion

August 8, 2024 7:02 AM ET Eli Lilly and Company (NYSE: LLY) today announced its impressive financial results for the second quarter of 2024.

Total WEB revenue increased by an impressive 36%, largely attributed to the strong performance of the company's key drugs Mounjaro, Zepbound, and Verzenio.

The company's net profit also saw a significant increase of 68%, reflecting the overall strength of its business.

Eli Lilly has revised its full-year revenue guidance upwards by $2 billion, indicating continued confidence in its future growth prospects.

Investors and analysts alike have praised Eli Lilly's strong quarterly performance, which bodes well for the company's long-term outlook.

For more information on Eli Lilly and Company's financial results and investor relations, visit their website at www.investor.lilly.com.